Amibegron

Amibegron

Systematic (IUPAC) name
Ethyl ([(7S)-7-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)acetate
Clinical data
Routes of administration	Oral
Legal status
Legal status	Development terminated
Identifiers
CAS Number	121524-09-2
ATC code	none
PubChem	CID 3035442
IUPHAR/BPS	568
ChemSpider	108738
UNII	PDQ3ME68U3
KEGG	D08851
ChEMBL	CHEMBL545437
Chemical data
Formula	C22H26ClNO4
Molar mass	403.898 g/mol
SMILES CCOC(=O)COc3ccc1CCC(Cc1c3)NCC(O)c2cc(Cl)ccc2
InChI InChI=1S/C22H26ClNO4.ClH/c1-2-27-22(26)14-28-20-9-7-15-6-8-19(11-17(15)12-20)24-13-21(25)16-4-3-5-18(23)10-16;/h3-5,7,9-10,12,19,21,24-25H,2,6,8,11,13-14H2,1H3;1H/t19-,21-;/m0./s1 Key:NQIZCDQCNYCVAS-RQBPZYBGSA-N
(verify)

Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis (now Sanofi) which acts as a selective agonist for the β₃ adrenergic receptor. It is the first orally active β₃ agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.^[1][2]

On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.^[3]

References

1. Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology. 2008 Feb;33(3):574-87. PMID 17460614
2. Overstreet DH, Stemmelin J, Griebel G. Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacology, Biochemistry and Behaviour. 2008 Jun;89(4):623-6. doi:10.1016/j.pbb.2008.02.020 PMID 18358519
3. Second quarter 2008 results. July 31, 2008, retrieved March 9, 2009.